Skip to main content
Clinical Trials/NCT01372631
NCT01372631
Completed
Not Applicable

A Novel Optical Spectral Imaging System for Imaging Breast Tumor Margins

Duke University2 sites in 1 country218 target enrollmentApril 2011
ConditionsBreast Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Duke University
Enrollment
218
Locations
2
Primary Endpoint
Identification of the optical signatures in breast tissue
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The goal of this research is to further develop novel optical assay systems for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens.

Detailed Description

The goal of this research is to further develop novel optical assay systems for intra operative assessment of tumor margins in partial mastectomy or mastectomy specimens. We are seeking to establish the accuracy of first and second-generation prototypes of technologies utilizing optical spectroscopy for intra operative margin assessment in partial mastectomy or mastectomy specimens. The aims associated with this research are as follows, (1) to evaluate the device-tissue interface on reduction mammoplasty specimens from a total of 20 patients, (2) to assess random and systematic errors of the new miniature system on mastectomy specimens from a total of 40 patients (3) to test the sensitivity, and specificity of the miniature spectral imaging system for margin assessment on excised partial mastectomy or mastectomy specimens from a total of 150 patients undergoing breast conserving surgery. Last patient's surgery took place in 2017 and recruitment remained open. Later the team encountered staffing issues; therefore the study status was updated to suspended. We recently made the decision to no longer attempt to enroll the remaining 2 subjects and focus on the data analysis only.

Registry
clinicaltrials.gov
Start Date
April 2011
End Date
April 1, 2017
Last Updated
5 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing a reduction mammoplasty OR
  • Patients undergoing a lumpectomy mastectomy for the treatment of an invasive or non-invasive breast malignancy
  • Age \> 18
  • Clinically detectable disease either by physical examination or radiographic studies
  • Patients of all ethnic and gender groups will be included. Protocol accrual will be reviewed annually to include a determination of minority and gender representation. If accrual demonstrates under-representation of any group with comparison to disease incidence in that group, appropriate measures will be undertaken to increase participation of patients of that minority or gender group
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  • Patients considered in "vulnerable" populations.

Outcomes

Primary Outcomes

Identification of the optical signatures in breast tissue

Time Frame: Day of procedure (less than 10 minutes)

Secondary Outcomes

  • Sensitivity and Specificity of the device(Day of procedure (less than 10 minutes))

Study Sites (2)

Loading locations...

Similar Trials